

Claims:

1. Pharmaceutical composition for the treatment of acute and/or chronic pain comprising calcium channel blockers which are capable of blocking voltage-dependent calcium channels.
2. Pharmaceutical composition as defined in claim 1 wherein the calcium channel is a T-type or L-type channel.
3. Pharmaceutical composition as defined in claim 1 or 2 for the treatment of allodynia or hyperalgesia.
4. Pharmaceutical composition according to any one of claims 1 to 3 wherein the calcium channel blocker is mibefradil, its pharmaceutically acceptable analogues, salts or esters or a dihydropyridine.
5. Pharmaceutical composition for the treatment of pain associated with rheumatoid arthritis, cancer, injuries, back pain, herpes zoster and post-operative pain.
6. Pharmaceutical composition according to any one of claims 1 to 5 for the topical, oral, parenteral, inhalative or intranasal administration.
7. Pharmaceutical composition according to claim 6 in form of an ointment, gel, crème or a solution or suspension, or plaster.
8. Pharmaceutical composition according to claim 6 in form of a nasal spray or inhalator.
9. Pharmaceutical composition according to any one of claims 1 to 3 for the systemic therapy of pain.
10. Pharmaceutical composition according to any one of claims 1 to 3 characterised in that tablets, capsules, coated tablets, granulates, juice, syrup, suspensions or solutions are used as oral forms of application.
11. Pharmaceutical composition according to any one of claims 1 to 3 characterised in that the drug form used is formed of biologically utilizable or

biodegradable substances wherein the biological materials are proteins or proteides, lipids or lipoids, carbohydrates or polysaccharides or mixtures of several of such materials.

12. Pharmaceutical composition according to any one of claims 1 to 3 characterised in that additionally one other pain killer is used.
13. Pharmaceutical composition according to claim 12 characterised in that the pain killer used in combination is an NSAID, a 5HT_{1D} agonist, a dopamin D₂ receptor antagonist, a secale alcaloid, a beta blocker, a calcium channel blocker or a neurokinin antagonist.
14. Pharmaceutical composition according to claim 12 characterised in that the NSAID is ibuprofen, meoxicam, indomethacin or naproxen.
15. Pharmaceutical composition according to claim 12 characterised in that the 5HT_{1D} agonist is sumatriptan, MK-452, naratriptan or 311C.
16. Pharmaceutical composition according to claim 12 characterised in that the dopamin D₂ receptor antagonist is metoclopramid.
17. Pharmaceutical composition according to claim 12 characterised in that the secale alcaloid is ergotamin, dihydroergotamin or metergolin.
18. Pharmaceutical composition according to claim 12 characterised in that the beta blocker is propranolol or metoprolol.
19. Pharmaceutical composition according to claim 12 characterised in that the calcium channel blocker is flunarizin or lomerizin.
20. Pharmaceutical composition according to claim 12 characterised in that the pain killer to be administered in combination is acetylsalicylic acid, paracetamol, clonidin, methysergid, dotarizin, lisurid, pizotifen, valproat, aminotriptilin CP-122,288 or UK 116,044.